Table 3.

Prognostic evaluation of clinical and histopatological characteristics of early stages: Progression Free Survival

Progression Free Survival - Univariated analysis
		HR	Lower 95% CI	Upper 95% CI	p-value
Age at diagnosis		1.04	1.00	1.07	0.024
Stage	I	1
	II	1.24	0.54	2.85	0.606
Grading	G1	1
	G2	1.95	0.63	5.97	0.245
	G3	2.63	0.89	7.77	0.081
Histotype	Serous	1
	Endometroid	0.46	0.17	1.26	0.132
	Clear cell	1.15	0.49	2.71	0.756
	Mucinous	0.59	0.17	2.04	0.404
	Undifferentiated	6.88	1.46	32.37	0.01
	Other	0.76	0.17	3.34	0.717
First line therapy	No therapy	1
	Platinum-based	0.79	0.40	1.58	0.510
KRAS status	Wild-type	1
	Mutated	0.85	0.33	2.19	0.736
KRAS gene copy number	Disomy	1
	Amplification	1.48	0.64	3.44	0.357
	Deletion	1.22	0.37	4.04	0.748
KRAS-LCS6 polymorphism	T/G-G/G	1
	T/T	1.08	0.45	2.60	0.865
Progression Free Survival - Multivariated analysis
		HR	Lower 95% CI	Upper 95% CI	p-value
KRAS-LCS6 polymorphism	T/G-G/G	1
	T/T	1.34	0.50	3.57	0.564